Merck Stock Surges 86.31% in Trading Volume Ranking 43rd with Positive Clinical Trial Results

On June 9, 2025, Merck (MRK) experienced a significant surge in trading volume, reaching $1.451 billion, marking an 86.31% increase from the previous day. This surge positioned Merck as the 43rd highest trading volume stock for the day. The company's stock price also saw a 0.46% increase, marking the second consecutive day of gains and a total increase of 2.20% over the past two days.

Merck recently announced positive topline results from the first two Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational oral PCSK9 inhibitor. The CORALreef HeFH and CORALreef AddOn trials successfully met their primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) for enlicitide compared to placebo and other oral non-statin therapies. There were no clinically meaningful differences in incidences of adverse events (AE) and serious adverse events (SAE) in either trial.

Enlicitide, a novel macrocyclic peptide, has the potential to be the first approved oral PCSK9 inhibitor. If approved, it would offer a daily oral pill form of treatment, providing antibody-like efficacy and specificity for the validated PCSK9 mechanism. This development is significant as atherosclerotic cardiovascular disease accounts for 85% of cardiovascular deaths, and despite available treatment options, cardiovascular-related deaths remain the leading cause of death worldwide.

Merck's focus on cardiovascular disease has a long history, with the company introducing its first cardiovascular therapy over 60 years ago. The company continues to strive for scientific excellence and innovation in all stages of research, from discovery through approval and life cycle management. Merck's efforts in this area aim to improve the lives of patients globally by advancing research that can help prevent and treat cardiovascular diseases.